Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes: BNT162b2 (Comirnaty; Pfizer-BioNTech), mRNA-1273 Vaccine (COVID-19 Vaccine Moderna; Moderna) and COVID-19 Vaccine (ChAdOx1-S [recombinant])(Vaxzevria, AstraZeneca)
Latest Information Update: 05 Jan 2024
Price :
$35 *
At a glance
- Drugs AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms IMCOVAS
- 05 Jan 2024 Status changed to completed.
- 01 Jan 2022 Planned number of patients changed from 840 to 560.
- 05 Aug 2021 New trial record